The grant is entitled “Bioengineered organs-on-chip models: A new approach to investigate the radiobiological effects of cancer radiotherapy ” and is funded under the Cancer Research theme of the University of South Australia.
This project will demonstrate the feasibility of using bioengineered “organs-on-chip” models to obtain quantitative radiobiological insights and accelerate the establishment of new research links with Prof Harald Paganetti (Radiation Oncology, Harvard University) and Dr Amir Aref (Dana Farber Cancer Institute, Harvard University) as well as with the French Biotech company Cherry Biotech.
Well done to Marnie, Meysam and all other co-authors for the publication of our review article “A Reappraisal of Circulating Fetal Cell Noninvasive Prenatal Testing” in Trends in Biotechnology.
Abstract: New tools for higher-resolution fetal genome analysis including microarray and next-generation sequencing have revolutionized prenatal screening. This article provides commentary on this rapidly advancing field and a future perspective emphasizing circulating fetal cell (CFC) utility. Despite the tremendous technological challenges associated with their reliable and cost-effective isolation from maternal blood, CFCs have a strong potential to bridge the gap between the diagnostic sensitivity of invasive procedures and the desirable noninvasive nature of cell-free fetal DNA (cffDNA). Considering the rapid advances in both rare cell isolation and low-input DNA analysis, we argue here that CFC-based noninvasive prenatal testing is poised to be implemented clinically in the near future.